Anson Funds Management’s GT Biopharma GTBP Stock Holding History

Anson Funds Management’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,456	Closed	-$133K	–	387
2021 Q4	$133K	Buy	+1,456	New	+$218K	0.01%	328

Other funds holding GTBP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Anson Funds Management's GTBP Position: Q1 2022 in Review

Anson Funds Management sold out of GT Biopharma (GTBP) in Q1 2022, closing a stake of 1,456 shares — an estimated $133K sold.

Anson Funds Management first reported a position in GTBP in Q4 2021 and held it in 1 quarter. The position peaked at $133K in Q4 2021. 57 funds tracked by Wall St. Rank hold GTBP as of Q1 2022.

Anson Funds Management reported no remaining GT Biopharma position as of Q1 2022 after selling out during the quarter.
Anson Funds Management sold 1,456 GT Biopharma shares in Q1 2022, an estimated $133K.
Anson Funds Management first reported a position in GT Biopharma in Q4 2021 and held it in 1 quarter.
Anson Funds Management's GT Biopharma position peaked at $133K in Q4 2021.
57 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.